Reducing Amyloid Plaque Deposits in the Brain with Anti-Complement Protein (80708)
- *Abstract
-
Features and Benefits
- A novel method for treating alzheimers.
- Can be used with or without other anti-Alzheimer's agents such as Cholinesterase inhibitors.
- Therapy should delay inflammation associated with SDAT and prevent further neurodegeneration.
*This Technology is available for licensing, further development, or industrial partnering*
Technology
Researchers at the University of Louisville have discovered a novel treatment for SDAT, comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the production of amyloid plaques in the brain of the patient. The vaccinia virus complement control protein (VCP) can inhibit up to 90% of A beta (a portion of the amyloid precursor protein) activated complement.
The vaccinia virus complement control protein, an inhibitor of both the classical and alternate pathway can be used to down-regulate the biologically significant activation of complement by amyloid beta, as demonstrated by an in vitro immunassay.
Markets Addressed
Senile dementia Alzheimer's Type (SDAT) disease affects a vast number of individuals over 60 years of age and is the 4th leading cause of death in the US with 4.5 million people suffering from it, yet limited treatment options are available. Current treatments have a limited effect on behavioral symptoms and alleviating the progression of neurodegeneration associated with SDAT. Researchers at the University of Louisville have discovered a novel treatment for SDAT, comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the production of amyloid plaques in the brain of the patient. This inhibition may alleviate the progression of some of the chronic neurodegeneration characteristic of Alzheimer's disease.
Technology Status
- IP Status: Issued
- Development Status: In vivo development needed.
- Fields of Use Available: All
- Publications: "Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein." Neurobiology of Aging 19 (6):619-27, 1998.
- Country/Region
- USA
